Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Stock designation, reported higher full-year net loss of US$67.85 million on US$4.41 million revenue for 2025, filed a US$23.24 million shelf registration, and received an auditor going concern warning, while advancing its OCU400 Phase 3 program toward planned 2026–2027 regulatory milestones. At the same time, Oppenheimer's new research coverage has drawn attention to Ocugen's late-stage gene therapy pipeline, especially OCU400's completed Phase 3 enrollment for retinitis pigmentosa and the prospect of multiple regulatory filings over the next three years. We'll now examine how OCU400's completed Phase 3 enrollment and looming regulatory milestones interact with Ocugen's investment narrative and risk profile. Uncover the next big thing with 29 elite penny stocks that balance risk and reward. Ocugen Investment Narrative Recap To own Ocugen today, you have to believe that OCU400's late stage gene therapy program can translate into an approved treatment for retinitis pigmentosa
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]Yahoo! Finance
- Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]Seeking Alpha
- Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]Seeking Alpha
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/5/26 - Form 3
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- OCGN's page on the SEC website